

## Editorial Advisory Board

### Editor-in-Chief

#### Ronald J. Oudiz, MD

Associate Professor of Medicine  
UCLA School of Medicine  
Director, Liu Center for Pulmonary  
Hypertension  
Division of Cardiology  
Los Angeles Biomedical Research  
Institute at Harbor-UCLA  
Medical Center  
Torrance, California

### Immediate Past Editor

#### Vallerie V. McLaughlin, MD

Associate Professor of Medicine  
Director, Pulmonary Hypertension  
Program  
University of Michigan Health System  
Ann Arbor, Michigan

### Editor-in-Chief Elect

#### Richard Channick, MD

Professor of Clinical Medicine  
Pulmonary and Critical Care Division  
University of California, San Diego Medi-  
cal Center  
San Diego, California

### Associate Editors

#### Erika Berman Rosenzweig, MD

Assistant Professor of Pediatrics  
Department of Pediatrics  
Columbia College of Physicians  
and Surgeons  
New York, New York

#### Todd Bull, MD

Associate Professor of Medicine  
Medical Director, ICU Anshutz  
Inpatient Pavilion  
Division of Pulmonary Sciences and  
Critical Care Medicine  
University of Colorado Health Sciences  
Center  
Denver, Colorado

#### Robert Schilz, DO, PhD

Medical Director of Lung Transplantation  
and Pulmonary Vascular Disease  
University Hospital of Cleveland  
Case Western Reserve University  
Cleveland, Ohio

### Editorial Board

#### Teresa De Marco, MD

Director, Heart Failure and  
Pulmonary Hypertension Program  
University of California, San Francisco  
San Francisco, California

#### Eli Gabbay, MD

Associate Professor  
University of Western Australia  
School of Medicine and Pharmacology  
Medical Director, Advanced Lung Disease  
and Pulmonary Vascular Unit  
Royal Perth Hospital  
Perth, Australia

#### Kristin Highland, MD

Assistant Professor  
Division of Pulmonary and Critical  
Care Medicine  
Director, Pulmonary Hypertension Clinic  
Medical University of South Carolina  
Charleston, South Carolina

#### Omar Minai, MD

Staff Physician  
Cleveland Clinic  
Cleveland, Ohio

#### Myung H. Park, MD

Director, Pulmonary Vascular  
Diseases Program  
University of Maryland School of  
Medicine  
Baltimore, Maryland

#### Ioana Preston, MD

Assistant Professor of Medicine  
Tufts-New England Medical Center  
Boston, Massachusetts

#### Zeenat Safdar, MD

Assistant Professor of Medicine  
Department of Medicine,  
Pulmonary & Critical Care Section  
Pulmonary Hypertension Center  
Baylor College of Medicine  
Houston, Texas

#### Rajan Saggat, MD

Assistant Professor of Medicine  
Division of Pulmonary and Critical Care  
Medicine and Hospitalists  
David Geffen School of  
Medicine at UCLA  
Los Angeles, California

#### Francisco Soto, MD

Assistant Professor  
Director, Pulmonary Hypertension  
Program  
Medical College of Wisconsin  
Milwaukee, Wisconsin

#### Fernando Torres, MD

Director, Pulmonary Hypertension  
Program  
UT Southwestern Medical Center  
Dallas, Texas

### Program Description

The mission of *Advances in Pulmonary Hyper-  
tension* is to serve as the premiere  
forum for state of the art information regarding  
diagnosis, pathophysiology, and treatment of  
pulmonary hypertension. The 2003 Venice re-  
vision of the World Health Organization Classi-  
fication serves as a guide to categories of  
pulmonary hypertension addressed by the Jour-  
nal. While focusing on WHO Group I PAH, the  
other categories (Group II, Left heart  
disease; Group III, Associated with lung dis-  
ease and/or hypoxemia; Group IV, Thrombotic  
and/or Embolic Disease; Group V, Miscellane-  
ous) are also addressed. This mission is  
achieved by a combination of invited review ar-  
ticles, Roundtable discussions with panels  
consisting of international experts in PH, and  
original contributions. In addition, a special  
section entitled "Profiles in Pulmonary Hyper-  
tension" recognizes major contributors to the  
field and serves as an inspiring reminder of the  
rich and collegial history of dedication to ad-  
vancing the field.

### Objectives

- Provide up-to-date information regarding di-  
agnosis, pathophysiology, and treatment of  
pulmonary hypertension.
- Serve as a forum for presentation and dis-  
cussion of important issues in the field, in-  
cluding new paradigms of disease  
understanding and investigational trial de-  
sign.
- Recognize and preserve the rich history of  
individuals who have made major contribu-  
tions to the field via dedication to patient  
care, innovative research, and furthering the  
mission of the PH community to cure pul-  
monary hypertension.

## The Scientific Leadership Council of the Pulmonary Hypertension Association

The scientific program of the Pulmonary  
Hypertension Association is guided by  
the association's Scientific Leadership  
Council. The Council includes the  
following health care professionals:

#### Vallerie V. McLaughlin, MD

SLC Chair  
University of Michigan Health System  
Ann Arbor, Michigan

#### David B. Badesch, MD

SLC Immediate Past Chair  
University of Colorado Health  
Sciences Center  
Denver, Colorado

#### John H. Newman, MD

SLC Chair Elect  
Vanderbilt Medical School  
Nashville, Tennessee

#### Robyn J. Barst, MD

New York, New York

#### Raymond L. Benza, MD

University of Alabama Health System  
Birmingham, Alabama

#### Todd Bull, MD

University of Colorado Health  
Sciences Center  
Denver, Colorado

#### Richard N. Channick, MD

UCSD Medical Center  
San Diego, California

#### C. Gregory Elliott, MD

LDS Hospital  
University of Utah School of Medicine  
Salt Lake City, Utah

#### Karen A. Fagan, MD

University of South Alabama  
College of Medicine  
Mobile, Alabama

#### Adaani Frost, MD

Baylor College of Medicine  
Houston, Texas

#### John Granton, MD

Toronto General Hospital  
Toronto, Canada

#### Nazzareno Galiè, MD

Institute of Cardiology  
University of Bologna  
Bologna, Italy

#### Nicholas S. Hill, MD

Division of Pulmonary, Critical Care  
and Sleep Medicine  
Tufts-New England Medical Center  
Boston, Massachusetts

#### Marius Hoeper, MD

Hannover Medical school  
Hannover, Germany

#### Dunbar Ivy, MD

University of Colorado Health  
Sciences Center  
Denver, Colorado

#### Zhi-Cheng Jing, MD

Fu wai Heart Hospital  
Beijing, China

#### Anne M. Keogh, MD

St. Vincent's Public Hospital  
Sydney, Australia

#### Michael J. Krowka, MD

Mayo Clinic  
Rochester, Minnesota

#### James E. Loyd, MD

Vanderbilt University Medical Center  
Nashville, Tennessee

#### Michael D. McGoon, MD

Chair, PHA Board of Trustees  
Pulmonary Hypertension Clinic  
Mayo Clinic  
Rochester, Minnesota

#### Srinivas Murali, MD

Allegheny General Hospital  
Pittsburgh, Pennsylvania

#### Ronald J. Oudiz, MD

Liu Center for Pulmonary Hypertension  
Los Angeles Biomedical Research  
Institute  
Harbor-UCLA Medical Center  
Torrance, California

#### Marlene Rabinovitch, MD

Stanford University School of Medicine  
Stanford, California

#### Erica Berman-Rosenzweig, MD

Columbia-Presbyterian Medical Center  
New York, New York

#### Ivan M. Robbins, MD

SLC Scientific Sessions Committee  
Vanderbilt University  
Nashville, Tennessee

#### Julio Sandoval, MD

Cardiopulmonary Department  
National Institute of Cardiology  
of Mexico  
Tlalpan, Mexico

#### Richard Silver, MD

Medical University of South Carolina  
Charleston, South Carolina

#### Victor F. Tapson, MD

Division of Pulmonary and Critical  
Care Medicine  
Duke University Medical Center  
Durham, North Carolina

### Liaisons

#### Arlene Schiro, RN, MA, ACNP-BC

Chair, PH Resource Network  
Massachusetts General Hospital  
Boston, Massachusetts

#### Joanne Sperando Schmidt

Patient Liaison

### Emeritus Members

#### Bruce H. Brundage, MD

St. Charles Medical Center-Bend  
Bend, Oregon

#### Alfred P. Fishman, MD

University of Pennsylvania Health  
System  
Philadelphia, Pennsylvania

*The Mission of the Scientific Leadership  
Council is to provide medical and scientific  
guidance and support to the PHA by:*

- Developing and disseminating knowledge  
for diagnosing and treating pulmonary  
hypertension
- Advocating for patients with pulmonary hy-  
pertension
- Increasing involvement of basic and clinical  
researchers and practitioners

More information on PHA's Scientific  
Leadership Council and associated  
committees can be found at:  
[www.PHAAssociation.org/SLC/](http://www.PHAAssociation.org/SLC/)